JP2021502984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502984A5 JP2021502984A5 JP2020526504A JP2020526504A JP2021502984A5 JP 2021502984 A5 JP2021502984 A5 JP 2021502984A5 JP 2020526504 A JP2020526504 A JP 2020526504A JP 2020526504 A JP2020526504 A JP 2020526504A JP 2021502984 A5 JP2021502984 A5 JP 2021502984A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- activation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- 230000004913 activation Effects 0.000 claims 10
- 208000009292 Hemophilia A Diseases 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000002797 proteolythic effect Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 2
- 208000031220 Hemophilia Diseases 0.000 claims 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 208000009429 hemophilia B Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000017854 proteolysis Effects 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17201762.6 | 2017-11-15 | ||
| EP17201762 | 2017-11-15 | ||
| EP18174634.8 | 2018-05-28 | ||
| EP18174634 | 2018-05-28 | ||
| PCT/EP2018/081296 WO2019096874A1 (en) | 2017-11-15 | 2018-11-15 | Factor x binders enhancing fx activation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021502984A JP2021502984A (ja) | 2021-02-04 |
| JP2021502984A5 true JP2021502984A5 (enExample) | 2021-12-02 |
Family
ID=64426877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526504A Pending JP2021502984A (ja) | 2017-11-15 | 2018-11-15 | Ｆｘ活性化を促進する第ｘ因子結合剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11787874B2 (enExample) |
| EP (1) | EP3710486B1 (enExample) |
| JP (1) | JP2021502984A (enExample) |
| CN (2) | CN118745229A (enExample) |
| MA (1) | MA50893A (enExample) |
| WO (1) | WO2019096874A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| US11787874B2 (en) * | 2017-11-15 | 2023-10-17 | Novo Nordisk A/S | Factor X binders enhancing FX activation |
| BR112021012065A2 (pt) | 2018-12-21 | 2021-12-07 | Kymab Ltd | Anticorpo biespecífico que se liga a fixa e fx e catalisa a ativação de fx mediada por fixa; método; anticorpo anti-fixa; anticorpo anti-fx; ácido nucleico isolado; célula hospedeira in vitro; população de células hospedeiras in vitro; kit para produção de um anticorpo biespecífico; método de produção de um anticorpo biespecífico; composição; método para controlar o sangramento em um paciente com hemofilia a; uso de um anticorpo biespecífico; método, composição para uso ou uso; e método para reduzir o desenvolvimento de anticorpos antifármacos inibidores em um paciente com hemofilia a em tratamento com um polipeptídeo que substitui a atividade de fviiia |
| JP2022548783A (ja) | 2019-09-23 | 2022-11-21 | ツイスト バイオサイエンス コーポレーション | 単一ドメイン抗体のバリアント核酸ライブラリー |
| US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
| US12258406B2 (en) * | 2021-03-24 | 2025-03-25 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| WO2023111018A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Antibodies against coagulation factor x and uses thereof |
| JP2025518552A (ja) * | 2022-05-16 | 2025-06-17 | セリントラ・セラピューティクス・エスア | 細胞を操作するための組成物及び方法 |
| CA3259753A1 (en) * | 2022-07-08 | 2024-01-11 | Novo Nordisk As | HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF REPLACED FVIII(A) |
| JP7459354B2 (ja) * | 2022-07-08 | 2024-04-01 | ノヴォ ノルディスク アー／エス | ＦＶＩＩＩ（ａ）の代わりとなることができる非常に効力があるＩＳＶＤ化合物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
| JPH08510555A (ja) | 1993-07-01 | 1996-11-05 | デイド、インターナショナル、インコーポレイテッド | 第ｘ因子除去血漿の調製のための方法 |
| WO2000007626A1 (en) | 1998-08-07 | 2000-02-17 | Smithkline Beecham Corporation | Use of anti-coagulation factor antibodies as long-lasting protective agents |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| JP2006520584A (ja) * | 2002-11-08 | 2006-09-14 | アブリンクス エン．ヴェー． | 安定化単一ドメイン抗体 |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| JP5490734B2 (ja) * | 2003-10-10 | 2014-05-14 | 中外製薬株式会社 | 機能蛋白質を代替する二種特異性抗体 |
| WO2005035753A1 (ja) * | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| EP1687338B1 (en) | 2003-11-07 | 2010-10-20 | Ablynx N.V. | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses thereof |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| JP4917024B2 (ja) | 2005-04-08 | 2012-04-18 | 中外製薬株式会社 | 血液凝固第ｖｉｉｉ因子の機能代替抗体 |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| SI2915564T1 (sl) | 2007-09-28 | 2021-03-31 | Alexion Pharmaceuticals, Inc. | Antidoti za zaviralce dejavnika Ksa in postopki njihove uporabe |
| TWI629355B (zh) * | 2010-11-17 | 2018-07-11 | 中外製藥股份有限公司 | 具有替代血液凝固第ｖｉｉｉ因子之功能的多重專一性抗原結合分子 |
| TWI831106B (zh) | 2014-06-20 | 2024-02-01 | 日商中外製藥股份有限公司 | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
| CA2978038A1 (en) | 2015-04-17 | 2016-10-20 | F. Hoffmann-La Roche Ag | Combination therapy with coagulation factors and multispecific antibodies |
| US20190185578A1 (en) | 2016-07-29 | 2019-06-20 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
| RU2766233C2 (ru) | 2016-09-06 | 2022-02-10 | Чугаи Сейяку Кабусики Кайся | Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x |
| CN110662770A (zh) | 2016-11-23 | 2020-01-07 | 比奥维拉迪维治疗股份有限公司 | 结合凝血因子ix和凝血因子x的双特异性抗体 |
| US11787874B2 (en) * | 2017-11-15 | 2023-10-17 | Novo Nordisk A/S | Factor X binders enhancing FX activation |
-
2018
- 2018-11-15 US US16/764,124 patent/US11787874B2/en active Active
- 2018-11-15 MA MA050893A patent/MA50893A/fr unknown
- 2018-11-15 CN CN202411097090.0A patent/CN118745229A/zh active Pending
- 2018-11-15 JP JP2020526504A patent/JP2021502984A/ja active Pending
- 2018-11-15 WO PCT/EP2018/081296 patent/WO2019096874A1/en not_active Ceased
- 2018-11-15 EP EP18807239.1A patent/EP3710486B1/en active Active
- 2018-11-15 CN CN201880073999.9A patent/CN111386285B/zh active Active
-
2023
- 2023-09-06 US US18/242,868 patent/US20230416404A1/en active Pending